Related Experiment Video

Updated: Jul 27, 2025

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.7K

MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors

Sylvia Yao Sun1, Aimee Crago2,3

  • 1Sarcoma Biology Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, 417 E 618 St, New York, NY 10065, USA.

Journal of Clinical Medicine
|June 10, 2023
PubMed

Insights

Murine double minute 2 (MDM2) oncogene overexpression degrades tumor suppressor p53, promoting tumor growth. Inhibiting MDM2 restores p53, offering a potential cancer therapy strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Murine double minute 2 (MDM2) is an oncogene encoding an E3 ubiquitin ligase.
  • MDM2 targets the tumor suppressor protein p53 for degradation via the 26S proteasome.
  • MDM2 overexpression inhibits p53-mediated cell cycle arrest and apoptosis, driving uncontrolled cell proliferation and tumor development.

Purpose of the Study:

  • To review the role of MDM2 in oncogenesis.
  • To explore MDM2 inhibition as a therapeutic strategy for soft-tissue tumors.
  • To present key milestones and potential applications of MDM2 research.

Main Methods:

  • Literature review of MDM2 and p53 interactions.
  • Analysis of MDM2's role in cell cycle regulation and apoptosis.
  • Discussion of therapeutic implications of targeting MDM2.

Main Results:

  • Cellular stress disrupts MDM2-p53 binding, increasing p53 levels and inducing cell cycle arrest or apoptosis.
  • Inhibition of MDM2 function can restore p53 activity, leading to tumor cell death.
  • MDM2 inhibition presents a promising therapeutic avenue for soft-tissue tumors.

Conclusions:

  • Restoring p53 function by inhibiting MDM2 is a viable strategy for cancer treatment.
  • Further research is crucial to establish the clinical safety and efficacy of MDM2-targeted therapies.
  • MDM2 research holds significant potential for advancing cancer therapeutics.
Keywords:
MDM2soft-tissue tumors

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.7K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.9K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K